Hereditary Transthyretin Amyloidosis Misdiagnosed as Demyelinating Neuropathy: A Report of Three Cases
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Transthyretin amyloidosis (aTTR) is a life-threatening type of systemic amyloidosis that has been associated with autosomal dominant mutations in the transthyretin gene. In this case series, we reviewed 3 patients initially treated for acquired demyelinating neuropathy that was later confirmed by pathologic testing and genetic analysis as aTTR. These patients had systemic symptoms and family records of sudden deaths that could not be explained by acquired demyelinating neuropathy. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a treatable neuropathy; however, 20% to 33% of CIDP patients remain refractory to conventional immunotherapy, and incorrect diagnoses might be the cause of this therapeutic failure. This case series revealed that the electrophysiological findings of aTTR could resemble the findings of demyelinating neuropathy.
Abstract
Transthyretin amyloidosis (aTTR) is a life-threatening type of systemic amyloidosis that has been associated with autosomal dominant mutations in the transthyretin gene. In this case series, we reviewed 3 patients initially treated for acquired demyelinating neuropathy that was later confirmed by pathologic testing and genetic analysis as aTTR. These patients had systemic symptoms and family records of sudden deaths that could not be explained by acquired demyelinating neuropathy. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a treatable neuropathy; however, 20% to 33% of CIDP patients remain refractory to conventional immunotherapy, and incorrect diagnoses might be the cause of this therapeutic failure. This case series revealed that the electrophysiological findings of aTTR could resemble the findings of demyelinating neuropathy.
참고문헌 (9)
- Ando Y, "Transthyretin-related familial amyloidotic polyneuropathy", Arch Neurol, 62, pp.1057~1062 (2005)
- Cocito D, "A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy", Eur J Neurol, 17, pp.289~294 (2010)
- Kaplan A, "Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy", Muscle Nerve, 55, pp.476~482 (2017)
- Allen JA, "CIDP diagnostic pitfalls and perception of treatment benefit", Neurology, 85, pp.498~504 (2015)
- Van den Bergh PY, "European Federation of Neurological Societies", Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision, 2010, pp.17, 356~363
- Breiner A, "Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy", Muscle Nerve, 50, pp.40~46 (2014)
- Lozeron P, "Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy", Neurology, 91, pp.e143~e152 (2018)
- Gondim FAA, "Transthyretin familial amyloid polyneuropathy due to lle107Val mutation mimicking atypical chronic inflammatory demyelinating polyneuropathy : case report", Acta Neurol Belg, 120, pp.201~203 (2020)
- Godil J, "Refractory CIDP : Clinical characteristics, antibodies and response to alternative treatment", J Neurol Sci, 418, pp.117098~ (2020)